CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
63.48
-1.61 (-2.47%)
At close: Feb 21, 2025, 4:00 PM
63.36
-0.12 (-0.20%)
After-hours: Feb 21, 2025, 7:50 PM EST
CVS Health Revenue
In the year 2024, CVS Health had annual revenue of $370.66B with 3.93% growth. CVS Health had revenue of $96.96B in the quarter ending December 31, 2024, with 3.65% growth.
Revenue (ttm)
$370.66B
Revenue Growth
+3.93%
P/S Ratio
0.22
Revenue / Employee
$1,235,520
Employees
300,000
Market Cap
80.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 370.66B | 14.03B | 3.93% |
Dec 31, 2023 | 356.62B | 34.99B | 10.88% |
Dec 31, 2022 | 321.63B | 30.72B | 10.56% |
Dec 31, 2021 | 290.91B | 23.00B | 8.59% |
Dec 31, 2020 | 267.91B | 12.14B | 4.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CVS News
- 14 hours ago - CVS cuts bonuses after low profit levels in 2024 - Reuters
- 2 days ago - Thermo Fisher Scientific Elects New Director to Board - Business Wire
- 3 days ago - My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys - Seeking Alpha
- 3 days ago - Top 2 cheap stocks to buy for 2025 - Invezz
- 3 days ago - CVS Health: One Good Quarter Is Not Enough; Retain Sell - Seeking Alpha
- 3 days ago - High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models - CNBC
- 4 days ago - Ed DeVaney named President of CVS Caremark - PRNewsWire
- 8 days ago - CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock - Benzinga